A Phase 2a/2b study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection. Revised Protocol 06, incorporating Protocol Amendments 03, 05, 06, 07, 08 and 10 + Amendment Number 09 Site-Specific - Ireland (1.0, dated 27-Oct-11).

Trial Profile

A Phase 2a/2b study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection. Revised Protocol 06, incorporating Protocol Amendments 03, 05, 06, 07, 08 and 10 + Amendment Number 09 Site-Specific - Ireland (1.0, dated 27-Oct-11).

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2014

At a glance

  • Drugs Asunaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 28 Apr 2013 Results reporting sustained virological response rates at 12 and 24 weeks post-treatment were presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
    • 27 Apr 2013 Primary endpoint 'Sustained-virological-response-rate' has been met.
    • 30 Jun 2012 Company added in the association field as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top